RxDoctor Payments Data

Michelle Swinyer, NP

Adult Health · Greensboro, NCNPI 1841923638

Payments from drug & device makers

$2,076in general payments, 2019–2025

Across 106 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$646
  • AstraZeneca$221
  • Novartis$165
  • Pfizer$122
  • Sanofi-aventis U.S. LLC$122
  • Boehringer Ingelheim$118
  • plus $683 from 15 others

What the payments were for

  • Food & beverage$2,076100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,076 in reported general payments places this provider in the 75th percentile of 614 adult health providers in North Carolina.

See all adult health providers in North Carolina

Medicare billing

Part B allowed, 2024
$19,695
Medicare patients
226
Services billed
365

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban148$109,508
EntrestoSacubitril/Valsartan70$65,329
JardianceEmpagliflozin39$38,694
Repatha SureclickEvolocumab61$38,485
FarxigaDapagliflozin Propanediol33$31,535
XareltoRivaroxaban31$25,326
Praluent PenAlirocumab13$7,507
NexlizetBempedoic Acid/Ezetimibe14$7,154
Rosuvastatin Calcium271$3,149
Ranolazine ErRanolazine14$3,142
Ezetimibe181$2,705
Metoprolol Succinate158$1,921
Diltiazem 24hr Er (Cd)Diltiazem Hcl55$1,653
Potassium Chloride106$1,454
Atorvastatin Calcium155$1,353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$122$109,508148 claims
NovartisEntresto$165$65,32970 claims
Boehringer IngelheimJardiance$118$38,69439 claims
AstraZenecaFarxiga$221$31,53533 claims
Johnson & JohnsonXarelto$81$25,32631 claims
Esperion Therapeutics, Inc.Nexlizet$64$7,15414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 614 adult health providers in North Carolina.

Other adult health in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →